Vaxart Yönetim

Yönetim kriter kontrolleri 3/4

Vaxart CEO'su Steven Lo, Mar2024 tarihinde atandı, in görev süresi 2.17 yıldır. in toplam yıllık tazminatı $ 2.81M olup, şirket hissesi ve opsiyonları dahil olmak üzere 23.1% maaş ve 76.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.23% ine doğrudan sahiptir ve bu hisseler $ 361.31K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 4.8 yıldır.

Anahtar bilgiler

Steven Lo

İcra Kurulu Başkanı

US$2.8m

Toplam tazminat

CEO maaş yüzdesi	23.13%
CEO görev süresi	2.2yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	4.8yrs

Son yönetim güncellemeleri

Recent updates

Yeni Anlatı • May 15

BARDA Reliance And Funding Risks Will Shape Oral Vaccine Prospects Longer Term

Catalysts About Vaxart Vaxart is a clinical stage biotechnology company developing oral pill vaccines for infectious diseases such as COVID 19 and norovirus. What are the underlying business or industry changes driving this perspective?

Analiz Makalesi • Jun 20

Vaxart, Inc. (NASDAQ:VXRT) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Vaxart, Inc. ( NASDAQ:VXRT ) shareholders would be excited to see that the share price has had a great month, posting a...

Analiz Makalesi • Feb 25

Lacklustre Performance Is Driving Vaxart, Inc.'s (NASDAQ:VXRT) 36% Price Drop

Vaxart, Inc. ( NASDAQ:VXRT ) shareholders won't be pleased to see that the share price has had a very rough month...

Analiz Makalesi • Jan 04

Revenues Not Telling The Story For Vaxart, Inc. (NASDAQ:VXRT) After Shares Rise 47%

Vaxart, Inc. ( NASDAQ:VXRT ) shareholders would be excited to see that the share price has had a great month, posting a...

Analiz Makalesi • Nov 16

Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

The Vaxart, Inc. ( NASDAQ:VXRT ) share price has fared very poorly over the last month, falling by a substantial 29...

Analiz Makalesi • Aug 20

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Vaxart, Inc. ( NASDAQ:VXRT ) shares have had a really impressive month, gaining 39% after a shaky period beforehand...

Analiz Makalesi • Jun 15

An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Key Insights The projected fair value for Vaxart is US$0.77 based on 2 Stage Free Cash Flow to Equity Current share...

Analiz Makalesi • Nov 08

Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Jun 30

Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO Tazminat Analizi

Steven Lo'un ücretlendirmesi Vaxart'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2026	n/a	n/a	US$37m
Dec 31 2025	US$3m	US$650k	US$16m
Sep 30 2025	n/a	n/a	-US$51m
Jun 30 2025	n/a	n/a	-US$57m
Mar 31 2025	n/a	n/a	-US$58m
Dec 31 2024	US$2m	US$474k	-US$67m

Tazminat ve Piyasa: Steven 'nin toplam tazminatı ($USD 2.81M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.66M ).

Tazminat ve Kazançlar: Steven 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Steven Lo (58 yo)

2.2yrs

Görev süresi

US$2,810,419

Tazminat

Mr. Steven Lo serves as President, CEO & Director of Vaxart, Inc. since March 18, 2024. From October 2019 to August 2022, Mr. Lo was the President, Chief Executive Officer and member of the board of direct...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Steven Lo	President	2.2yrs	US$2.81m	0.23% $ 361.3k
Sean Tucker	Senior VP & Chief Scientific Officer	16.3yrs	US$1.14m	0.15% $ 239.4k
James Cummings	Chief Medical Officer	4.8yrs	US$1.25m	0.15% $ 236.4k
Jeroen Grasman	CFO, Principal Accounting Officer & Principal Financial Officer	1yr	Veri yok	0.23% $ 351.8k
Edward Berg	Senior VP & General Counsel	4.3yrs	Veri yok	0.11% $ 173.0k
Laurie Hastings	Senior Vice President of Human Resources	1.3yrs	Veri yok	Veri yok
Rajesh Kapoor	Senior Vice President of Quality	5.3yrs	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: VXRT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Steven Lo	President	2.2yrs	US$2.81m	0.23% $ 361.3k
Harry Greenberg	Member of Scientific & Clinical Advisory Board	4.8yrs	Veri yok	Veri yok
Elaine Heron	Independent Director	3.8yrs	US$141.52k	0.033% $ 52.0k
Stanley Plotkin	Member of Scientific & Clinical Advisory Board	4.8yrs	Veri yok	Veri yok
Stefan Gravenstein	Member of Scientific & Clinical Advisory Board	4.8yrs	Veri yok	Veri yok
George R. Siber	Member of Scientific & Clinical Advisory Board	4.8yrs	Veri yok	Veri yok
David Wheadon	Independent Director	5.1yrs	US$152.97k	0.013% $ 19.8k
Robert Belshe	Member of Scientific & Clinical Advisory Board	4.8yrs	Veri yok	Veri yok
William Watson	Lead Independent Director	3.8yrs	US$143.95k	0.045% $ 69.7k
Marion Pepper	Member of Scientific & Clinical Advisory Board	4.8yrs	Veri yok	Veri yok
Ralph Baric	Member of Scientific & Clinical Advisory Board	4.8yrs	Veri yok	Veri yok
Gregory Gray	Member of Scientific & Clinical Advisory Board	4.8yrs	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

76yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: VXRT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/26 19:25
Gün Sonu Hisse Fiyatı	2026/05/22 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Vaxart, Inc. 5 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Mayank Mamtani	B. Riley Securities, Inc.
Roger Song	Jefferies LLC
null null	Oppenheimer & Co. Inc.

Vaxart Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Vaxart, Inc., Annual General Meeting, Jul 16, 2026

Vaxart, Inc. Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors

Vaxart, Inc. Announces Retirement of Michael J. Finney from the Board of Directors and Science and Technology Committee, Effective September 30, 2025

Vaxart, Inc., Annual General Meeting, May 21, 2025

Vaxart, Inc. Announces Board and Committee Changes

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Recent updates

Vaxart, Inc., Annual General Meeting, Jul 16, 2026

BARDA Reliance And Funding Risks Will Shape Oral Vaccine Prospects Longer Term

Vaxart, Inc. to Report Q1, 2026 Results on May 07, 2026

Vaxart, Inc. Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors

Vaxart, Inc. announced that it expects to receive $25 million in funding from Lincoln Park Capital, LLC

Vaxart, Inc. Publishes Positive Data for Its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants

Vaxart, Inc. to Report Q3, 2025 Results on Nov 13, 2025

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Vaxart Receives a Letter from the Office of the General Counsel of Nasdaq

Richard John Burgess Responds to Vaxart’s Governance Announcements

Vaxart, Inc. Reports Additional Phase 1 Data Supporting the Potential Efficacy of Its Second-Generation Norovirus Oral Vaccine Candidate

Richard John Burgess Files an Exempt Solicitation Statement with Vaxart

Vaxart, Inc. Announces Retirement of Michael J. Finney from the Board of Directors and Science and Technology Committee, Effective September 30, 2025

Richard John Burgess Urges Vaxart’s Shareholders to Vote Against Reverse Stock Split

Richard John Burgess Oppose Vaxart’s Latest Reverse Stock Split

Vaxart, Inc. to Report Q2, 2025 Results on Aug 13, 2025

Vaxart, Inc.(NasdaqCM:VXRT) dropped from S&P Global BMI Index

Vaxart, Inc.(NasdaqCM:VXRT) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Vaxart Common Stock, Suspends Trading Effective July 08

Vaxart, Inc. (NASDAQ:VXRT) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Vaxart, Inc. Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

New major risk - Financial position

Vaxart, Inc. Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

New major risk - Share price stability

Consensus revenue estimates increase by 171%

First quarter 2025 earnings released: US$0.068 loss per share (vs US$0.14 loss in 1Q 2024)

Vaxart, Inc. Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2B Covid-19 Trial

New major risk - Revenue and earnings growth

Price target increased by 24% to US$6.00

Vaxart, Inc. to Report Q1, 2025 Results on May 13, 2025

Vaxart, Inc., Annual General Meeting, May 21, 2025

New minor risk - Market cap size

Consensus revenue estimates decrease by 77%, EPS upgraded

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

No longer forecast to breakeven

Vaxart, Inc. to Report Fiscal Year 2024 Results on Mar 20, 2025

Vaxart, Inc. Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Lacklustre Performance Is Driving Vaxart, Inc.'s (NASDAQ:VXRT) 36% Price Drop

Vaxart, Inc. Enters into Modification No. 5 (The “Modification”) to the ATI-RRPV Project Award Agreement

Vaxart, Inc. Announces Board and Committee Changes

New major risk - Shareholder dilution

Vaxart Highlights Progress of Covid-19, Norovirus and Influenza Programs

Vaxart Announces Favorable Dsmb Review of Sentinel Cohort from Covid-19 Phase 2B Clinical Trial

Revenues Not Telling The Story For Vaxart, Inc. (NASDAQ:VXRT) After Shares Rise 47%

Vaxart, Inc. Provides Nasdaq Bid Price Non-Compliance Update

New minor risk - Share price stability

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Vaxart, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Vaxart, Inc. Announces Initiation of Sentinel Cohort for Phase 2B Study Evaluating its Covid-19 Oral Pill Vaccine Candidate

New major risk - Financial position

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia

Consensus revenue estimates increase by 113%, EPS downgraded

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Vaxart, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Vaxart Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Consensus revenue estimates increase by 865%

An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Vaxart, Inc. Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Price target increased by 11% to US$5.25

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Vaxart, Inc. to Report Q1, 2024 Results on May 13, 2024

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Now 27% overvalued after recent price rise

Vaxart, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes